MedTrace Logo

Platelet Transfusion Refractoriness

NCT05399693 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-01-05

No results posted yet for this study

Summary

Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.

Conditions

  • Platelet Transfusion Refractoriness

Interventions

PROCEDURE

platelet transfusion

platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia

Sponsors & Collaborators

  • Institut de cancérologie Strasbourg Europe

    lead OTHER

Principal Investigators

  • Luc FORNECKER · Institut de cancérologie Strasbourg Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-02
Primary Completion
2023-08-08
Completion
2023-08-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05399693 on ClinicalTrials.gov